An ever-increasing population of patients with papillary thyroid cancer is engaging with health care systems around the world. Numerous questions about optimal management have arisen that challenge conventional paradigms. This is particularly the case for patients with low-risk disease, who comprise most new patients. At the same time, new therapies for patients with advanced disease are also being introduced, which may have the potential to prolong life. This review discusses selected controversial issues in adult papillary thyroid cancer management at both ends of the disease spectrum. These topics include: (i) the role of active surveillance for small papillary cancers; (ii) the extent of surgery in low-risk disease (lobectomy vs total thyroidectomy); (iii) the role of postoperative remnant ablation with radioiodine; (iv) optimal follow-up strategies in patients, especially those who have only undergone lobectomy; and (v) new therapies for advanced disease. Although our current management is hampered by the lack of large randomized controlled trials, we are fortunate that data from ongoing trials will be available within the next few years. This information should provide additional evidence that will decrease morbidity in low-risk patients and improve outcomes in those with distant metastatic disease.
P apillary thyroid cancer, the most common endocrine malignancy, offers important public health and individualized treatment challenges to policy makers and clinicians. The rapidly rising incidence of papillary cancer, coupled with mostly excellent long-term survival, has created a large prevalent population of patients. Although most of these patients do well, the biology of papillary cancer is extremely diverse, ranging from nonprogressive/ extremely indolent lesions to aggressive metastatic cancers. Patients at low risk of thyroid cancer death can still have important or even catastrophic morbidity (including invasion of trachea, esophagus, large cervical vessels, and recurrent laryngeal nerves). Our ability to identify those facing adverse outcomes remains imperfect. All treatments have risks. Finally, hardly any treatment decisions in papillary thyroid cancer care have rigorous randomized controlled trial evidence to support their adoption, although often contradictory observational research on papillary thyroid cancer treatment continues to proliferate. Thus, there are many ongoing debates about optimal papillary thyroid cancer management.
Clinicians managing patients with papillary thyroid cancer have a multitude of sources to consult, including comprehensive but variably updated international treatment guidelines (-). Many other excellent recent summaries, including in Endocrine Reviews (), focus on a comprehensive discussion of treatment of low-risk papillary cancers. In this review, we aim to provide an up-to-date analysis of the key open debates in adult papillary thyroid cancer care across its spectrum of disease, offer a roadmap for optimizing personalized care in the face of evidence uncertainty, and explore how the evidence gaps may be bridged in the future.
The Rising Incidence of Papillary Thyroid Cancer
The exponential, nearly worldwide increase in papillary thyroid cancer incidence has been well described. Although this rising incidence began in the s, the intense research focus on explaining the phenomenon developed in the early s and continues today (, ).
It is extremely likely that increased diagnosis of small, clinically silent tumors (often termed "overdiagnosis") has occurred. The preconditions for overdiagnosis of thyroid cancer are clearly present. First, a reservoir of subclinical papillary cancer exists in many people; this has been most famously documented on autopsy specimens of cohorts who died of nonthyroid causes (). Second, we have the technologic ability to identify these silent tumors, whether it be through advanced imaging techniques of ultrasound, CT, MRI, or [  F]fluoro--deoxyglucose positron emission tomography (  F-FDG-PET) scans (), or by systematic microscopic examination of thyroid tissue after surgical removal (). Knowledge of small tumors being caught "early" and successfully treated and, conversely, a fear of missing treatable disease when localized are powerful motivators in both patients and clinicians to perform diagnostic procedures. When these procedures diagnose cancer, a positive feedback loop could be created to identify more disease and increase cancer incidence rates further ().
Although the phenomenon of overdiagnosis has probably occurred worldwide, the Korean experience is the most extreme example. Thyroid ultrasound became a common screening tool in the early s (even though not part of the official cancer screening program) (, ). The age-standardized incidence of papillary thyroid cancer (both sexes) rose from . cases per , persons per year in  to . cases per , persons per year in  (). The vast majority of diagnoses were of small, localized tumors (); nodules as small as  mm in diameter were documented to undergo fine-needle aspiration ().
There are numerous potential harms from cancer overdiagnosis. Otherwise healthy individuals may have significant psychologic distress from becoming a "cancer patient." Diagnosis usually leads to cancer treatments, with potential complications from unnecessary surgery or radioiodine treatment. Patients with thyroid cancer have been documented to have significant impairments in quality of life (, ), which could be related to either or both of these factors. There may be considerable personal financial costs related to cancer therapy, even leading to bankruptcy (). In addition to personal costs, the societal financial costs of medical care through insurance programs (both government and private) are large (). For thyroid cancer clinics, there may also be an opportunity cost from these medical services being overburdened with cases of extremely low-risk disease, preventing care and attention to patients at higher risk. Finally, patients with overdiagnosed cancers may be included in research studies assessing causes of disease or optimal treatments, and could therefore contaminate the research findings ().
Difficult challenges exist in reducing overdiagnosis harm. Not all incidental diagnosis can be avoided; for example, small tumors may be identified during appropriate medical assessment for symptoms potentially due to thyroid cancer, or on histologic examination of surgical specimens resected for benign compressive ESSENTIAL POINTS · The rising incidence of differentiated thyroid cancer may be due to "overdiagnosis" but may also be due to environmental exposures, which thus far remain uncertain · Many small papillary thyroid cancers are indolent, and many do not require surgery; additionally, newer less invasive therapies (e.g., radiofrequency ablation, laser) are being developed · For low-risk disease, lobectomy provides outcomes similar to total thyroidectomy with decreased perioperative morbidity: total thyroidectomy is indicated when there is preoperative evidence for more advanced disease, when more invasive disease is discovered intraoperatively, or when postoperative histology dictates completion thyroidectomy followed by adjuvant radioiodine therapy · Radioactive iodine therapy has not been shown to improve disease-specific mortality or recurrence rates in patients with low-risk disease, particularly patients whose postoperative unstimulated serum thyroglobulin is ,0.5 ng/mL · Postoperative unstimulated thyroglobulin and neck ultrasound remain the mainstays of follow-up of low-risk patients; however, persistent but low serum thyroglobulin levels have a very low positive predictive value for current structural disease · Newer therapies with multikinase inhibitors and redifferentiation strategies hold great promise in patients with advanced disease, but thus far, data from randomized trials do not unequivocally demonstrate improved overall survival goiter (). Clinicians also face the dilemma of how to distinguish an "overdiagnosed tumor" from one that would cause clinical harm in the future if left unattended. Finally, some patients with small, incidentally identified cancers may feel psychological benefit from having a diagnosis made and treatment performed.
Therefore, we require a multipronged public health approach that attempts to reduce unnecessary diagnosis and the harm resulting from diagnosis. Table  conceptualizes possible solutions within a modified Haddon matrix incorporating peridiagnostic time points and factors where interventions could be targeted (patients, diagnostic technology and definitions, and health care providers and environment). Some evidence suggests that initial efforts to prevent overdiagnosis are having an effect, with an apparent slowing of the incidence rise in the United States () and a reducing (but still very high) incidence rate in Korea ().
A key question is whether all of the increase in papillary cancer incidence is due to overdiagnosis. This is an important issue, because if environmental causes of thyroid cancer are driving part of the increased papillary cancer incidence, a singular focus on overdiagnosis prevention could be harmful by preventing earlier identification of clinically significant disease. Several lines of evidence support a "true" increase in thyroid cancer incidence. The incidence of large thyroid cancers as well as small tumors has increased (-). The incidence of advanced papillary cancers [e.g., those with lymph node or distant metastases (, , ), aggressive subtypes such as tall cell variants (), or significant extrathyroidal extension (, )] have also increased. Finally, a rise in papillary thyroid • Encourage use of conservative procedures (e.g., lobectomy)
Postdiagnosis
• Develop formal decision aids for patients to consider less invasive treatment options (e.g., active surveillance, lobectomy, withholding radioiodine) and be aware of success of treatment options in unlikely event of recurrence • Refine postdiagnosis risk stratification • Monitor and publish outcomes for less invasive treatment approaches in incidentally or potentially overdiagnosed disease cancer mortality has been reported in the United States (), as well as in Korea before  (with a subsequent decline thereafter) (). Counterarguments have been made: larger tumors may be incidentally diagnosed through imaging (); modern surgical and staging approaches could conceivably lead to upstaging of disease over time; and prior US incidence-based mortality rates were higher in the s than now (). Thus, current upward trending rates could represent statistical noise (although this argument assumes no improvements over time in directed or supportive treatments of patients with advanced cancer).
With the possibility/probability that a portion of the rising thyroid cancer incidence is due to changes in environmental exposures, a steady expansion in efforts to define papillary cancer risk factors has occurred. However, much of the evidence remains preliminary. Table  (-) discusses proposed risk factors examined in epidemiologic studies. One particular difficulty in interpreting the literature is the potential for confounding by diagnosis, that is, the inclusion of "overdiagnosed" patients who might never manifest clinical disease (assuming that overdiagnosed patients have different exposure profiles than do patients with clinical disease). Ideally, studies should be powered to include enough patients with clinically significant cancer to assess exposure-disease associations in these patients and/or assess putative risk factor associations with molecular markers of disease severity (e.g., BRAF VE mutations).
Initial Therapy of Papillary Thyroid Cancer
Should all cancers be treated? Most patients with papillary thyroid cancer have an excellent prognosis. This is especially true for those with the smallest tumors, the papillary microcarcinomas (defined as diameter , mm). Given our knowledge of overdiagnosis and its associated harms, an important question is whether all diagnosed papillary cancers (particularly microcarcinomas) need treatment.
The pioneering work of Miyauchi and colleagues (-) at Kuma Hospital (Kobe, Japan) has provided essential data on the natural history of papillary microcarcinomas. From  on, most patients with biopsy-proven papillary microcarcinomas were offered either immediate surgery or observation (commonly called active surveillance; exclusion criteria were nodal or distant metastases, concern of high-grade malignancy on biopsy, and potential for tracheal or recurrent laryngeal nerve invasion). The latest outcomes study assessing  patients who chose active surveillance reports no thyroid cancer deaths, no distant metastases, .% development of nodal metastases at  years, and % with tumor enlargement $ mm at  years (). The risk of disease progression was highest in the youngest patients: -year disease progression for patients in their s was .%, progressively declining with each decade of age to .% for patients in their s (). Numbers of patients in the active surveillance group who experienced complications from their treatment were significantly fewer than for patients who chose immediate surgery (reflecting fewer patients being exposed to surgery, even when treated in a very highvolume institution) (). The -year cost of active surveillance vs immediate surgery appears to be lower, at least in the Japanese setting ().
Other groups have published early data that support active surveillance approaches for papillary microcarcinomas. The longest running program from the Cancer Institute Hospital (Tokyo, Japan) (-) reports nearly identical results to the Kuma Hospital group for patients with microcarcinomas (the latest report for  patients with mean followup of . years documents no thyroid cancer deaths, no distant metastases, % development of nodal metastases, and % with tumor enlargement $ mm) (). The first American report, which was from the Memorial Sloan-Kettering Cancer Center, described tumor growth $ mm in diameter in  of  patients with microcarcinomas (.%) during a median follow-up of . years (). Researchers from Asan Medical Center (Seoul, Korea) report that  of  patients with papillary microcarcinomas observed without surgery during a median follow-up of . years had a diameter increase of $ mm (). Finally, in  patients with microcarcinomas followed with active surveillance for a median follow-up of . years at Samsung Medical Center (Seoul, Korea) seven nodules grew $ mm in diameter, and  patient had nodal metastasis (). In the latter three analyses, the change in tumor volume was proposed to be a more sensitive measure of growing tumors than tumor diameter.
The above data support a choice for biopsy-proven microcarcinoma, that is, either immediate treatment or active surveillance. The current American Thyroid Association (ATA) guidelines for the management of thyroid nodules and thyroid cancer cautiously acknowledge this choice, and they also call for further studies to define the role of active surveillance (). However, the guidelines also state that thyroid nodules without accompanying lymphadenopathy should not undergo fine-needle aspiration until $ mm in diameter (recommendation ), even when highsuspicion ultrasound features are present (); previous guidelines also discouraged biopsy of small lesions, although they were less prescriptive (, ). Clinicians following the ATA guidelines for nodule diagnosis are therefore performing active surveillance by default on a subset of their patients, because some of them will have microcarcinomas. The active • The best-defined risk factor for papillary thyroid cancer, although the increased risk is only established following exposure in childhood and adolescence (35) . Radiation exposure has increased in the United States; however, most of this is due to radiation from CT and nuclear medicine scans (36) , which are rare before 20 y of age. The prevalence of known radiation-induced genetic signatures is declining in new papillary cancer cases (37, 38) . Without new evidence, it seems unlikely that radiation is the cause of rising thyroid cancer incidence.
Smoking
• Most evidence suggests a 30% to 40% reduced risk of thyroid cancer in active smokers (39) (40) (41) . There is a reducing prevalence of smoking in most countries (42) . Although it is plausible that some of the incidence rise for papillary cancer could be due to declining smoking rates, this is not directly actionable for thyroid cancer prevention given smoking's overwhelming harms. The association is, however, worthy of future research to explore potential mechanisms of causation.
Alcohol
• Most studies suggest a 20% to 30% reduced risk of thyroid cancer in those with moderate alcohol consumption (43) . It is unlikely that alcohol consumption has significantly dropped in most countries where thyroid cancer incidence is increasing, and therefore it is unlikely to be a major cause of the rising incidence.
Dietary
• Iodine: iodine deficiency is associated with higher follicular and anaplastic thyroid cancer rates. Transitioning a population from iodine deficiency to sufficiency increases the proportion of papillary cancer diagnoses, and high iodine intake may be associated with papillary thyroid cancer (44) . However, the incidence of papillary cancer has also increased in countries where iodine status is essentially unchanged.
• Nitrates/nitrites: the relationship between exposure to nitrates and nitrites in food and water to thyroid cancer risk has been examined in several large cohort studies (45-47) (additionally, other studies have assessed nitrate-containing cruciferous vegetable intake; see below). Results are inconsistent, and it is unclear whether any real relationship exists.
• Vegetable intake: small, mostly retrospective studies suggested associations between intake of cruciferous vegetables and thyroid cancer risk, as well as inverse associations between noncruciferous vegetable intake and thyroid cancer risk (48) . These findings have not been confirmed by a recent large prospective cohort study (49) .
Environmental toxins
• Flame retardants: one small study suggests that exposure to specific retardants increases thyroid cancer risk (50) . Two other studies were negative for a flame retardant-thyroid cancer relationship, although they assessed different flame retardants (51, 52) . Exposure to flame retardants has increased over time. Further research is required.
Medications, particularly hormonal
• Women undergoing fertility treatments have been reported to be at increased risk of thyroid cancer diagnosis (53) . Interpreting these results is very difficult, because of the heterogeneous causes of infertility, the generally short exposure to hormonal fertility treatments, the potential for incidental thyroid cancer diagnosis, and the lack of supporting evidence from other studies assessing reproductive factors (see below).
Intrinsic
Body size • Body weight and obesity: many, but not all, studies suggest that an increase in body mass index is associated with risk of thyroid cancer [e.g., in a pooled analysis of body mass index measured at various time points in 22 prospective studies, for each 5 kg/m 2 increase in body mass index, the risk of thyroid cancer increased by 6% to 13% (54)]. Although there is the potential for obesity to be associated with increased medical presentation and thus incidental diagnosis, obesity has been linked with more aggressive tumor features and increased risk of thyroid cancer mortality in patients with obesity (54) . The prevalence of obesity is increasing worldwide. This association is worthy of continued attention.
• Height: increasing height is associated with increased thyroid cancer risk (similar to many other cancers) (54) . This association is not actionable, although understanding the mechanism of the association could advance knowledge for numerous cancer types.
Metabolic factors
• There is very little evidence for altered thyroid cancer risk in patients with diabetes, hyperlipidemia, or metabolic syndrome, despite numerous studies.
Serum TSH concentration and autoimmunity
• Cross-sectional studies suggest papillary thyroid cancer diagnosis associated with higher serum TSH concentration (55) and Hashimoto thyroiditis (56) . These studies cannot rule out the effect of selection bias and confounding, and prospective studies could also be prone to these biases. Indeed, two prospective studies yield contradictory findings for a serum TSH-thyroid cancer relationship (57, 58) . Both studies find lower serum TSH to be associated with thyroid cancer diagnosis, yet only one finds higher TSH also to be associated with risk (58) . Lower serum TSH concentration is plausibly related to thyroid cancer risk via thyroid autonomy with greater TSH pathway signaling; however, it could also be due to incidental diagnosis in patients treated surgically for thyrotoxicosis. Further research is needed. Future studies assessing Hashimoto thyroiditis as a risk factor for thyroid cancer should demonstrate prospective ascertainment of thyroid autoimmunity and use methods of assessing for potential ascertainment.
Estrogen and reproductive factors
• The female preponderance for thyroid cancer remains unexplained. Reproductive and hormonal factors have been extensively investigated with mostly negative results (or very weak and inconsistent associations if positive) (48) . Autoimmunity is more common in women, although autoimmunity has not been proven to cause thyroid cancer (as above).
surveillance data suggest this "default" approach is safe for the vast majority of patients. Future research will improve clarity on which patients are at highest risk of disease progression with active surveillance for proven or potential papillary microcarcinomas, and thereby positively impact clinical management.
A papillary microcarcinoma has an arbitrary metric definition (, mm), but most patients with intrathyroidal papillary cancers $ mm in diameter also have an excellent prognosis. Two small studies have reported on the outcomes for active surveillance for papillary cancers $ mm in diameter. The Memorial Sloan-Kettering study mentioned above included  patients with tumors  to  mm in diameter;  had an increase in tumor diameter $ mm and  had a tumor volume increase $% (). The Cancer Institute Hospital reported results for  patients with tumors  to  mm in diameter (mean follow-up of . years) (). There were no deaths, no patients with distant metastases, two patients with nodal metastases, four patients with an increase in tumor diameter $ mm, and seven patients with a $% increase in tumor volume.
Nonsurgical therapies for papillary microcarcinomas, including low-power microwave ablation (), radiofrequency ablation (), and laser ablation (), are novel and potentially useful therapies for papillary microcarcinomas.
Surgical approaches
For almost all papillary cancers needing treatment, surgery is the key therapy. The goals of surgery are to remove the primary tumor, minimize the risk of disease recurrence, provide accurate staging, and to allow radioiodine to be delivered, when appropriate. Accurate preoperative assessment is critical to surgical decision-making. The main surgical options are extent of thyroidectomy (either total thyroidectomy or lobectomy) and whether to perform neck nodal dissection (no dissection or central with or without ipsilateral dissection); the optimal approach remains controversial today.
Preoperative assessment
Ultrasound is widely accepted as the first-line imaging technique for preoperative assessment in papillary thyroid cancer. However, ultrasound accuracy is operator-dependent, and even with skilled sonographers, it may not fully appreciate the extent of disease in certain neck locations (particularly the upper mediastinum, retropharyngeal space, and posterior to the thyroid for tracheal invasion and tracheoesophageal disease). A recent meta-analysis also suggested that the combination of ultrasound and contrast-enhanced CT was superior to either technique alone in identifying cervical node metastases (). Surgeons should therefore strongly consider preoperative cross-sectional imaging (i.e., contrast-enhanced CT) where there is any doubt as to ultrasound quality when disease is suspected at locations where inadequate ultrasound images are likely (e.g., large posterior nodules), or for clearly aggressive cancers where cross-sectional imaging may assist in identifying additional nodal metastases. Although it is true that administering IV contrast with CT imaging will necessitate a delay in any radioiodine treatment, this time may be less than traditionally recommended () and any disease that is radioiodine sensitive at the time of surgery is likely to remain so  to  months postoperation.
One tantalizing future possibility is the use of preoperatively identified molecular markers (i.e., via fine-needle aspiration) to guide treatment intensity. These could conceivably identity low-and high-risk phenotypes and be used to prevent overtreatment of likely indolent disease or undertreatment of tumors with high-risk molecular features. At present, data are insufficient to recommend this approach.
Lobectomy verses total thyroidectomy
The pendulum continues to swing regarding the extent of surgery required in papillary cancer. Ten years ago, the  ATA thyroid cancer guidelines recommended total thyroidectomy for all papillary cancers . mm in diameter and stated that lobectomy may be sufficient for low-risk, unifocal, intrathyroidal microcarcinomas (). These recommendations were based on data from the US National Cancer Database, which suggested a survival advantage in patients with thyroid cancers $ mm in diameter who had more complete surgery (). However, that study was extremely controversial, with other large population-based data set analyses (-), including a reexamination of the National Cancer Database (), showing no survival benefit from total thyroidectomy compared with lobectomy in low-risk patients. Single-center cohorts also confirm an extremely low mortality and recurrence risk in patients undergoing lobectomy (), at the expense of a small increased risk of recurrence in some (-), but not all, studies (). All current guidelines now suggest lobectomy for intrathyroidal papillary microcarcinomas. More controversially, these guidelines support either total thyroidectomy or lobectomy for most patients with papillary cancers  to  mm in diameter and without extrathyroidal extension or clinical evidence of lymph node metastasis (-). Guidelines continue to support total thyroidectomy in those patients with the largest tumors or high-risk preoperative clinical features, and completion thyroidectomy for those patients with higher risk histologic features.
Lobectomy has the clear advantage of fewer surgical complications. Compared with total thyroidectomy, lobectomy patients experience less hypocalcemia and recurrent laryngeal nerve injury (, ). Most lobectomy patients will also not need thyroid hormone replacement (, ).
Despite data suggesting low risk of adverse cancer outcomes and lower chance of adverse surgical effects with lobectomy, the debate over the optimal extent of surgery persists (). The strongest argument for total thyroidectomy is to allow better individualized postoperative risk stratification and surveillance, including via radioiodine scanning and serum thyroglobulin measurement. Postlobectomy dynamic risk stratification data show promising early results, but the numbers of supporting studies are small (-) and cutpoints for serum thyroglobulin response are not well defined (see "Tailoring follow up strategies to the extent of initial treatment" below) (). It is therefore understandable that some clinicians seek to minimize uncertainty by advocating more extensive treatment. Another suggested reason for total thyroidectomy is that adverse histologic features (e.g., tall cell variant of papillary cancer, follicular cancer with vascular invasion) can be found in lobectomy specimens, which may lead to completion thyroidectomy (although the data suggest that this applies to a minority of patients, when using very strict criteria for mandating completion thyroidectomy based on histologic features) (). It has also been argued that because the contralateral lobe may harbor additional cancers (mainly microcarcinomas ()), total thyroidectomy would prevent the need for reoperation. However, it is likely that many contralateral microcarcinomas would never progress clinically, and seeking them in total thyroidectomy specimens could constitute a form of overdiagnosis. In studies from the Memorial Sloan-Kettering Cancer Center that have compared local recurrence rates with lobectomy vs total thyroidectomy without radioiodine remnant ablation, no differences in locoregional recurrence rates were seen in  patients [thyroid lobectomy (n 5 ) or total thyroidectomy (n 5 )] after a median of  years of follow-up (), and similar findings were seen in a similar retrospective cohort of  patients (lobectomy, n 5 ; total thyroidectomy, n 5 ) with a median of  years of follow-up, with locoregional recurrence rates of ,% in both surgical groups (). It is reasonable to suggest that a second surgery in the rare patient with locoregional recurrence is preferable to subjecting all patients to what is likely unnecessary surgery in most. Furthermore, a recent populationbased study found a higher rate of adverse quality-oflife issues and/or treatment-related effects in patients who had undergone total thyroidectomy (excluding those who also had lateral neck dissections) compared with those who had undergone a lobectomy (OR, .; % CI, . to .) ().
A key question for clinicians and patients considering conservative surgery is what specific diseaserelated features should preclude lobectomy or lead to completion thyroidectomy, taking into account patient preferences and health system expertise. A closely related consideration is whether radioiodine ablation should be performed, given that total thyroidectomy is almost always a prerequisite for this (). Clearly, preoperative evidence of gross extrathyroidal extension, nodal metastatic disease, or distant metastases mandates a total thyroidectomy, and the presence of contralateral benign disease might favor a total thyroidectomy. It is critical for the surgeon to discuss the possibility of the need to convert a planned lobectomy to a total thyroidectomy with or without central neck dissection, based on intraoperative findings that were not apparent on preoperative imaging (e.g., extrathyroidal extension, recurrent nerve involvement, clearly pathologic adenopathy). The identification of very low-risk histologic diagnoses [e.g., noninvasive follicular tumors with papillary-like features ()] would argue against completion thyroidectomy following diagnosis on lobectomy. Figure  describes a framework for planning the surgical approach for preoperatively diagnosed papillary thyroid cancer. As mentioned above, we anticipate that in the future, preoperatively or postoperatively available somatic genomic/molecular profiles will be validated to assist with the personalization of surgical treatment decisions. At present, the data are insufficient to recommend using BRAF mutation (or any other gene's) status in this decision-making, although the ATA differentiated thyroid cancer guidelines include BRAF status as part of their modified initial risk stratification criteria ().
Extent of neck dissection
After resolving the extent of thyroidectomy, the next key surgical issue is to determine the extent of neck nodal dissection, if any.
Where no clinical evidence of nodal disease metastasis exists (either preoperatively or intraoperatively), the treating surgeon must decide whether to perform "prophylactic" central node dissection of level VI of the neck [prelaryngeal, pretracheal, and paratracheal lymph nodes bound superiorly by the hyoid, laterally by the carotids, and inferiorly by the innominate artery on the right and the corresponding axial plane on the left ()], which may be a bilateral dissection but is often performed only on the ipsilateral side to the primary tumor. Proponents suggest that prophylactic central node dissection regularly identifies nodal disease and potentially reduces recurrence risk and need for reoperation in a scarred surgical field. Additionally, increased staging and risk stratification information is available postoperatively. However, not resecting microscopic central cervical nodal metastases that would be identified by prophylactic central node dissection does not appear to influence the prognosis of low-risk papillary cancer (, ), and the only randomized controlled trial evidence available (albeit in a small study) does not show an effect on recurrence risk (). Increased staging information for clinicians also risks prompting excessive postoperative treatment (e.g., radioiodine) from upstaging patients' disease (). Finally, although the risks of permanent surgical morbidity such as recurrent laryngeal nerve injury and hypoparathyroidism are low in some series, increased rates of these complications have been reported in other settings (). On balancing these issues, the ATA concludes that not performing prophylactic central node dissection is appropriate for patients with smaller, lower-risk papillary cancers (i.e., intrathyroidal T and T tumors) ().
There is clear consensus for compartmental neck dissection of involved neck areas (as opposed to simply "berry picking" clinically abnormal nodes). If the central neck (level VI) is the only area clinically involved, targeting this compartment is likely sufficient; however, more extensive lateral neck dissection is required for lateral (Nb) nodal disease. Whether or not to operate within level V in the modified lateral neck dissection for patients with Nb papillary cancer is also uncertain; surgeons must balance the potential benefit of reducing the chance of disease persistence or recurrence with the risk of spinal accessory nerve damage ().
Postoperative radioiodine therapy
There are perhaps few controversies more heated in the thyroid cancer field than whether radioiodine should be used routinely following total thyroidectomy for patients with low-risk papillary thyroid cancer. Part of the difficulty is perhaps the failure to distinguish between remnant ablation and adjuvant therapy, which are both under the rubric of "postoperative radioactive iodine therapy." In low-risk patients, radioiodine is used in two contexts: (i) "remnant ablation" to destroy remnant tissue remaining after surgery, which may improve staging based on a posttreatment scan, and which theoretically will allow more specific follow-up with diagnostic radioiodine scanning and serum thyroglobulin measurements; and (ii) adjuvant therapy, given to destroy "occult" disease in those low-risk patients who may be at higher risk for recurrence, but that will not improve disease-specific survival. In addition to the semantic problem, the lack of prospective randomized controlled trials showing benefit from radioiodine therapy, particularly in low-risk patients, is an additional difficulty leading to disagreements among various professional groups (, , ).
The ambiguity between remnant ablation and "adjuvant therapy" is illustrated by two randomized controlled trials showing that high-dose ( mCi) and low-dose ( mCi) radioiodine therapy using either withdrawal or recombinant human TSH were equivalent in achieving remnant ablation (, ). One might ask whether the administration of  mCi of radioactive iodine constitutes remnant ablation or adjuvant therapy. In any event, although neither trial was designed to assess long-term outcomes in patients with thyroid cancer, both trials have reported on rates of residual/recurrent disease after long-term follow-up. Neither showed a difference among any of the treatment arms: for the HiLo study, recurrence rates were .% vs .% at  years, .% vs .% at  years, and .% vs .% at  years [hazard ratio (HR)], .; % CI, . to .; P 5 .) for low-and high-dose groups, respectively (). For the second study (ESTIMABL), the recurrence rate was % at a median follow-up time of . years, again with no difference between the highand low-dose radioiodine groups (). There are two randomized controlled trials, IoN (NCT) and ESTIMABL (NCT), which will provide vital information, as both trials have a "no therapy" arm. These studies are ongoing and should provide the needed information about the usefulness of postoperative radioiodine therapy.
Although there is evidence from retrospective studies of improved outcomes possibly in older patients and those with intermediate-risk disease (, ), the overwhelming majority of patients have lowrisk disease. In such patients, there are currently no data to support the use of radioactive iodine therapy for remnant ablation or for adjuvant therapy (, ). The ATA guidelines stress that "RAI [radioiodine] remnant ablation is not routinely recommended after thyroidectomy for ATA low-risk DTC [differentiated thyroid cancer] patients. Consideration of specific features of the individual patient that could modulate recurrence risk, disease follow-up implications, and patient preferences are relevant to RAI decision-making" (). Unfortunately, recent data show that the decision to administer radioiodine therapy in low-risk patients in the United States is often driven by nonclinical factors, such as geography, ethnicity, and insurance status (). To bridge some of the gaps in practice between endocrinologists and nuclear medicine physicians, leaders from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association recently published a set of "guiding principles" related to radioiodine therapy for differentiated thyroid cancer that will hopefully lead to less variation in practice ().
Given modern highly sensitive serum thyroglobulin assays, as well as high-resolution ultrasound, some have argued that the need for remnant ablation in lowrisk patients is no longer necessary (). Indeed, if the goal of remnant ablation is to achieve an undetectable serum thyroglobulin, some have wondered whether remnant ablation is even ethical in patients who already have very low or undetectable postoperative serum thyroglobulin levels (). There is little evidence to support routine remnant ablation in such patients (-). Even in patients not receiving remnant ablation who do not have undetectable postoperative serum thyroglobulin levels, these levels tend to decrease substantially over time, often becoming undetectable (). Furthermore, there is also a decrease in thyroglobulin autoantibody titers over time in low-risk patients not undergoing postoperative radioiodine therapy ().
In addition to the controversy about the true efficacy of radioiodine therapy, its role has become less relevant in , because lobectomy, with its advantages of safety and potential preservation of thyroid function, is becoming an ever more popular surgical approach to the management of low-risk thyroid cancer (, ). In patients undergoing lobectomy, completion thyroidectomy would only be considered in "patients for whom a bilateral thyroidectomy would have been recommended had the diagnosis been available before the initial surgery" (), and mainly done to facilitate radioiodine therapy. In patients with intermediate-risk disease with lowerrisk features (e.g., small central neck lymph nodes), who have undergone total thyroidectomy (either at the outset or after completion thyroidectomy), the ATA recommends low-dose radioiodine therapy ( mCi; recommendation A) (). In contrast, activities up to  mCi are recommended for those patients with large remnants or who have suspected residual disease for whom adjuvant therapy is indicated (recommendation B) (). However, whether radioiodine will improve outcomes in such patients will not be known until the results of IoN and ESTIMABL are published. With that, there hopefully will be broader agreement on the use of postoperative radioiodine in low-risk disease, which accounts for the vast majority of patients with thyroid cancer ().
Thyroid hormone suppression therapy: is it necessary?
Because TSH is a growth factor for thyroid tissue and thyroid cancer, the idea that maintaining a low serum TSH would benefit patients with thyroid cancer has been a cornerstone of thyroid cancer treatment for more than half a century (, ). However, older studies often did not distinguish between replacement and suppression therapy, and they lacked the ability to detect low-volume recurrences using thyroglobulin measurements and high-resolution ultrasound. More recent studies have not shown a benefit from aggressive suppression therapy (undetectable serum TSH in a third-generation TSH assay) or even less severe degrees of TSH suppression (i.e., serum TSH ,. mU/L) in patients with low-risk disease (, -). In contrast, one retrospective study noted a strong survival benefit of maintaining serum TSH levels ,. mU/L in patients with advanced disease (). There has been only one randomized controlled trial in which patients' serum TSH levels were adjusted to remain within the reference range vs levels ,. mU/L (). In this study, no difference in disease-free survival was noted after almost  years of follow-up, including in a separate analysis of high-risk patients.
One major benefit of thyroid lobectomy vs total thyroidectomy in low-risk disease is the possibility that patients may not need postoperative thyroid hormone therapy. Recent studies have shown that a preoperative serum TSH .. mU/L () or . mU/L () is a predictor of postoperative hypothyroidism, especially when anti-TPO antibodies are positive (). A retrospective study showed that patients whose serum TSH levels were maintained ,. mU/L with levothyroxine after lobectomy fared no better than did patients whose serum TSH levels were allowed to remain between . and . mU/L (). However, there was a difference in the frequency of incomplete biochemical responses between the two groups, with patients not receiving levothyroxine having a higher rate compare with patients whose serum TSH levels were maintained ,. mU/l (.% vs .%). Note that patients in this study who underwent lobectomy also had an ipsilateral prophylactic central neck dissection, making comparisons with patients who have only undergone a lobectomy difficult.
In addition to dubious benefits in low-risk patients, long-term suppression of serum TSH can result in a number of adverse consequences, including cardiovascular disease (), atrial fibrillation (-), osteoporosis (), and risk of fractures (). These negative effects of iatrogenic exogenous subclinical hyperthyroidism on the heart and skeleton are most striking in older individuals and in postmenopausal women, respectively. Current ATA guidelines recommend no TSH suppression in low-and intermediate-risk patients who have had an excellent response to treatment (serum TSH levels of . to . mU/L), but they recommend mild TSH suppression (serum TSH levels . to . mU/L) in high-risk patients who have had an excellent response to therapy (). Mild TSH suppression is also recommended for patients who have an incomplete biochemical response to therapy. More aggressive suppression (serum TSH ,. mU/L) is recommended for those patients with residual structural disease or a biochemically incomplete response when the patient is young, premenopausal, or is at low risk for developing cardiovascular complications. The guidelines also emphasize ongoing risk assessment of the patient's thyroid cancer status, as well as the patient's potential comorbidities, older age, menopausal status, and the interim development of cardiovascular disease. Other clinical guidelines suggest similar schemas (-).
Key Decisions in Follow-Up
Tailoring follow-up strategies to the extent of initial treatment With practice guidelines (-) recommending riskadapted management of papillary thyroid cancers, defining follow-up strategies tailored to initial treatment is mandatory. This is especially critical, as the adoption of these guidelines will lead to an increase in conservative surgeries (). However, although current guidelines clearly outline the follow-up protocols to be applied to patients who have had a total thyroidectomy (with or without radioiodine remnant ablation), there are no clear, straightforward recommendations on the assessment schedule that should be adopted in patients with papillary thyroid cancer who have undergone lobectomy. This is mainly because most evidence comes from patient cohorts who have undergone the traditional extensive therapeutic approach.
In patients who have had a total thyroidectomy (with or without radioiodine), a disease-free status (also known as excellent response) comprises undetectable serum thyroglobulin levels (basal or TSH stimulated), in the absence of interfering antibodies, and no clinical and imaging evidence of tumor (, , ). Thyroglobulin has a central place in this definition of "cure," because when structural recurrence occurs, a positive thyroglobulin result is usually identified before abnormal imaging. A new generation of highly sensitive thyroglobulin assays, characterized by a much improved analytical sensitivity, have been endorsed by current international guidelines () and are becoming more common in clinical practice. By applying these methods, serum thyroglobulin levels ,. ng/mL during TSH suppression or , ng/ mL after TSH stimulation reliably identify those patients who remain disease-free over time; the negative predictive value is close to % (-). Because sensitive measurements of basal thyroglobulin provide similar information on disease status as do stimulated thyroglobulin determinations, TSH stimulation may be avoided if sensitive assays are available. Regardless of the method used, thyroglobulin levels should always be interpreted in light of the pretest probability of clinically significant residual tumor. In low-to intermediate-risk patients who have undetectable serum thyroglobulin and no structural evidence of disease on neck ultrasound at initial assessment (excellent response to therapy), the future recurrence risk is ,% (, ). These patients can be safely followed with periodic (every  to  months) serum thyroglobulin and thyroglobulin antibody assays and neck palpation, without routine use of ultrasonography. Repeated neck ultrasound assessment in these patients may lead to more false-positive findings (up to %) than true disease (,.%) (, ). Undetectable thyroglobulin levels in patients with initially high-risk cancers may require additional, second-line diagnostic procedures to rule out disease (see the following section), as the absence of the circulating tumor marker may simply reflect the dedifferentiation of the residual neoplastic foci and their loss of ability to synthesize or secrete thyroglobulin. Alternatively, minimally detectable thyroglobulin values in individuals at low to intermediate risk carry a very lowpositive predictive value (), and a significant proportion of patients with a biochemically indeterminate response (basal thyroglobulin . to . ng/mL) or a biochemically incomplete response (basal thyroglobulin $ ng/mL) to therapy remain free of structural disease during prolonged follow-up (-). In these patients, the thyroglobulin trend may be helpful in correctly classifying them, in that declining values predict a disease-free status, whereas rising levels suggest the presence of growing neoplastic foci (, ). The presence of thyroglobulin autoantibodies can falsely lower immunometrically determined thyroglobulin levels (). Alternative biochemical approaches to follow thyroglobulin autoantibody-positive patients include: (i) using radioimmunoassay or liquid chromatography-tandem mass spectrometry for thyroglobulin measurements (), as they resist thyroglobulin autoantibody interference (however, the functional sensitivity is much lower, being . to  ng/mL); (ii) using highly sensitive thyroglobulin assay and applying lower thyroglobulin thresholds than in patients without thyroglobulin antibodies (); and (iii) assessing the temporal trend in thyroglobulin autoantibody titers (, ).
However, for postlobectomy patients, a thyroglobulincentered definition of disease status is problematic and is supported by much less evidence. Here, thyroglobulin assay results cannot discriminate between a "benign" thyroglobulin from the residual thyroid lobe, and a "malignant" thyroglobulin from small-volume residual disease. Reliable thyroglobulin cutoffs for distinguishing these two states have not been established, and the role of serum thyroglobulin assay trends has to be determined. A cutoff of  ng/mL has been proposed to discriminate between patients having or not having an excellent response to therapy (-). Although this value has yet to be validated, many conditions are expected to introduce wide variability in thyroglobulin levels among subjects with a residual thyroid lobe. These include the volume of the residual thyroid tissue, the TSH levels, and the iodine supply. Based on all of these considerations, neck ultrasound is universally regarded as the essential tool for assessing the response to initial treatment in patients treated with lobectomy (-). Because a conservative management approach is reserved for low-risk patients, in the few cases that recur after lobectomy, disease is almost always localized to the neck (, ). These recurrences may involve the ipsilateral thyroid bed and lymph nodes, as well as the contralateral lobe, which can all be sonographically identified using wellestablished criteria (-). Similar to thyroglobulin assays, neck ultrasound has a high sensitivity, but the specificity may be lowered by false-positive findings (, -). Watchful waiting is thus appropriate for low-volume lesions, whereas fineneedle aspiration cytology or thyroglobulin/molecular assays of needle washout fluid (, ) may be warranted to confirm malignancy in those lesions with documented structural disease progression and who will undergo further treatment if recurrent disease is confirmed (). The ATA guidelines set the short-axis nodal diameter cutoff for when to biopsy at  mm for central neck nodes, and  mm for lateral neck nodes (). However, many other additional factors should be taken into account when considering surgical options. These include the risk of revision surgery (e.g., proximity of the nodal lesions to vital structures, functional status of the vocal cords), primary tumor factors (e.g., histology or molecular patterns associated with aggressive behavior), and patient factors (e.g., age, comorbidities, patient preference).
What to do with rising thyroglobulin levels Among patients who have had complete thyroid gland removal, with or without postoperative radioiodine therapy, the proportion of patients with serum thyroglobulin levels above the disease-free (excellent response) cutoff value ranges from % to % (). Although patients with low but detectable serum thyroglobulin levels (, ng/mL) and no structurally identifiable neck lesions at ultrasound are expected to remain disease-free during prolonged follow-up (, ), individuals with higher values or rapidly increasing values (i.e., doubling time , year) are more "Before considering a patient as eligible for systemic therapies, a thorough assessment should be performed to assess whether one or more lesions are amenable for localized treatments." prone to have or to develop a structural recurrence (, , ). In these cases, second-line imaging studies may be warranted to detect persistent tumor foci (Fig. ) . The diagnostic work-up may include functional (whole-body radioiodine scanning and  F-FDG-PET scanning) and cross-sectional (CT or MRI) studies (, ). It is noteworthy that  F-FDG-PET has a much higher sensitivity than the posttherapeutic whole-body scan (% vs %), and it can also provide prognostic information (, ). Avidity with  F-FDG is most commonly seen in the more aggressive histological papillary thyroid cancer variants (), radioiodine-refractory disease (), patients with thyroglobulin levels . ng/mL or rapidly increasing (i.e., doubling time , year) (), and after TSH stimulation () [although conflicting results have been reported on this issue; thus, TSH-stimulated  F-FDG is not routinely recommended in the clinical practice ()]. The option of the empiric radioiodine treatment may be considered in patients in whom cross-sectional studies or  F-FDG-PET have failed to reveal a tumor source (). However, there is no evidence that such an approach improves survival, and watchful waiting until disease is detected on anatomic imaging remains an option.
Advanced Papillary Thyroid Cancer Management
Current management with multikinase inhibitor therapy Whereas one third of the patients with papillary thyroid cancer with radioiodine-avid metastatic disease can be successfully treated with therapeutic radioiodine activities, the remaining patients do not benefit from repeated radioiodine administrations. The overall -year survival rate drops from % in the first group to % in the second (). The latter group may be eligible to move from a radionuclide-targeted cancer therapy to a kinase-targeted therapy.
Proposed characteristics for a patient having radioiodine-refractory thyroid cancer include: target lesions that do not take up radioactive iodine either on diagnostic or posttreatment radioiodine scanning (even when accompanied by radioiodine-avid lesions); or progression despite a substantial radioiodine uptake or a cumulative radioiodine activity of .. GBq ( mCi) (, ). These features can be of help in identifying patients who may qualify for systemic treatment, in the presence of symptomatic or significantly progressive metastatic disease [ Fig.  (-) ]. Before considering a patient as eligible for systemic therapies, a thorough assessment should be performed to assess whether one or more lesions are amenable for localized treatments. This applies especially to those individuals with one or a few areas of metastatic spread (oligometastases), or multiple lesions with an isolated area of progression (oligoprogression). A variety of approaches are available, including surgery, radiotherapy, or percutaneous minimally invasive techniques (e.g., ablation of metastatic lesions with laser, radiofrequency energy, microwaves, cryotherapy, radioembolization, or chemoembolization) (, ) Additionally, for skeletal metastases, low level-of-evidence data support a benefit of bone resorption inhibitors (bisphosphonates and denosumab) in potentially decreasing the skeletalrelated events (e.g., pathological fractures, spinal-cord compression) and improving pain (, ). For patients with radioiodine-refractory papillary thyroid cancer eligible for systemic therapy, two options are approved by the European Medicines Agency and US Food and Drug Administration: sorafenib and lenvatinib. Both are oral multikinase inhibitors with antiangiogenic activity, and both have been investigated in large, randomized phase  trials: DE-CISION () and SELECT (), respectively. Both studies showed a statistically significant improvement in progression-free survival (the primary endpoint) compared with placebo. For sorafenib, the median progression-free survival was . vs . months for placebo (HR, .; % CI, . to .; P , .), whereas for lenvatinib, the median progression-free survival was . vs . months for placebo (HR, .; % CI, . to .; P , .). No significant difference in overall survival was observed in either trial, possibly related to the fact that the patients in the placebo groups were allowed to "cross over" to active therapy at the end of the trials. However, in a prespecified subgroup analysis of the lenvatinib trial, a significant improvement in overall survival emerged in patients aged . years (). Both multikinase inhibitors can cause important adverse events and require close monitoring; specific management strategies may minimize their incidence and severity (). Although the main goal of cancer therapies is improving the quantity and quality of patients' lives, whether these drugs are able to improve the quality of life has not been characterized.
Beyond these two agents (i.e., sorafenib and lenvatinib), no additional therapies are currently approved for treating patients with advanced, radioiodinerefractory papillary thyroid cancer. When disease progression occurs for patients treated with multikinase inhibitors, clinicians have several options. For oligoprogression, patients may benefit from combining a localized treatment with the ongoing therapy (albeit after a short treatment break from the multkinase inhibitor to ensure wound healing and/or recovery from any toxicity). For patients experiencing generalized treatment failure of one agent, data from the SELECT study support switching multikinase inhibitor, because patients experiencing treatment failure with one prior multikinase inhibitor had a clinical benefit from subsequent lenvatinib treatment (). For generalized failure after using both agents, patients may be assessed for suitability for clinical trial recruitment, if any are available (see the following section). In the absence of ongoing and recruiting clinical trials, the National Comprehensive Cancer Network guidelines suggest additional kinase inhibitor alternatives that have been approved by the US Food and Drug Administration for other cancers, and for which evidence for treatment Figure 3 . Management of patients with advanced papillary thyroid cancer. a Patients with metastatic disease that does not take up radioactive iodine (RAI) at the time of initial treatment, or that loses the ability to take up RAI after previous evidence of 131 I uptake, or with RAI uptake in some lesions but not in others, or with metastatic disease that progresses despite substantial uptake of RAI. b Patients who received RAI cumulative activities .22.2 GBq (600 mCi) are less likely to benefit from further 131 I administrations. c A single organ or a single/few lesions should be considered for localized treatments. d The size and location(s) should be considered in determining whether asymptomatic diseases at potentially critical sites (e.g., cerebral, peritracheal, perivascular, bony, paraspinal) require earlier treatment. e Disease progression should be evaluated through serial imaging at 3-to 6-mo intervals. Significant disease progression includes an increase in tumor size between two time points of at least 20% according to the Response Evaluation Criteria in Solid Tumors (RECIST) system and/or a tumor doubling time (the time after which the diameter/volume of the lesions has doubled) ,1 y (179) (180) (181) . efficacy in thyroid cancer may be derived from phase  or phase  studies (including axitinib, cabozantinib, dabrafenib, everolimus, pazopanib, sunitinib, vandetanib, and vemurafenib) (). Of note, access to these drugs may not be available in all countries.
Future targeted therapies
Other classes of drugs are being studied in patients with papillary thyroid cancer and hold promise for treating patients with advanced, radioiodine-refractory disease. An exciting area of research that may lead to new drug treatments involves the modulation of thyroid cancer differentiation, aimed at restoring radioiodine uptake in cancer cells that are unable or have lost the ability to take up the radioiodine (so-called redifferentiation). Several unsuccessful attempts have been made in past years from this perspective (). However, recently, two kinase inhibitors [selumetinib (a selective MEK inhibitor) and dabrafenib (a selective BRAF inhibitor)] targeting the MAPK pathway have been used to reinduce radioiodine uptake in patients with radioiodine-refractory thyroid cancer (-). Almost two thirds of patients exhibited new or increased radioiodine uptake, with a partial radiologic and clinical response being observed in % to % of the cases. These experiences should be considered "proof-of-concept" studies, involving a small proportion of patients. Larger prospective studies are needed to confirm these results to determine the duration of response, the impact on survival, and the characteristics of patients who are most likely to benefit from therapy.
Other exploratory, promising approaches include the use of agents targeting "druggable" mutations, such as BRAF or TRK. BRAF inhibitors (i.e., vemurafenib and dabrafenib) showed antitumor activity (partial response) in almost one third of the patients with progressive, radioiodine-refractory, BRAF VE mutant papillary cancer (-). Cotargeting the downstream MEK protein with a MEK inhibitor (i.e., trametinib) plus BRAF inhibitor (i.e., dabrafenib) has been shown to be effective in treating BRAF VE mutant undifferentiated thyroid carcinoma (), which likely arose from papillary cancer. This has led the US Food and Drug Administration to approve trametinib/dabrafenib combination for treating anaplastic thyroid carcinoma harboring this genotype. In a phase  study enrolling patients with TRK fusionpositive cancers, the novel TRK-directed agent larotrectinib was reported to yield a partial response rate of % in the subgroup of cases with TRK-rearranged papillary thyroid cancer (n 5 ) (). It is likely that additional targeted approaches for advanced papillary thyroid cancers, including targeted immunotherapy, will be developed in the future ().
Although all of these approaches hold promise as being effective in treating advanced, radioiodinerefractory papillary thyroid cancers, the indications for each, and their long-term efficacy and safety profile remain to be clarified.
